跳至主要内容
临床试验/NCT02032654
NCT02032654终止4 期

Duration of Antibiotic Therapy for Cellulitis (DANCE): a Randomized Controlled Trial Comparing 6 to 12 Days of Antibiotic Therapy for Patients Hospitalized With Cellulitis

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)11 个研究点 分布在 1 个国家目标入组 151 人开始时间: 2014年8月26日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
终止
入组人数
151
试验地点
11
主要终点
Part 1/2: Resolution...

研究概览

简要总结

Cellulitis is among the most common infections leading to hospitalization, yet the optimal duration of therapy remains ill defined. Pragmatically, Dutch guidelines advise 10-14 days of antibiotics, which is the current standard of care. Recently it has been shown that antibiotic treatment for pneumonia and urinary tract infections can safely and significantly be shortened. Importantly, in an outpatient setting, treatment of uncomplicated cellulitis with 5 days of antibiotics was as effective as 10 days. We hypothesize that there is no difference in outcomes when patients hospitalized with cellulitis are treated with either a short-course (6 days) or standard-course (12 days) of antibiotics.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Admitted to receive intravenous antibiotics for cellulitis/erysipelas
  • 18 years of age or older
  • Capable of giving written informed consent, able to comply with study requirements and restrictions

排除标准

  • Allergy for flucloxacillin, other beta-lactam antibiotics or one of the additives, or flucloxacillin induced hepatitis or liver enzyme disorders.
  • Concurrent use of antibiotics for other indications
  • Alternative diagnosis accounting for the clinical presentation.
  • All cases involving any of the following complicating factors:
  • Use of antibiotics with Gram-positive activity for more than 4 days in the past 7 days
  • Intensive care unit admission during the last 7 days
  • Severe peripheral arterial disease (Fontaine IV)
  • Severe cellulitis necessitating surgical debridement or fascial biopsy
  • Necrotizing fasciitis
  • Periorbital or perirectal involvement
  • Life expectancy less than one month
  • Risk factors associated with Gram-negative pathogens as a causative agent:
  • Chronic or macerated infra-malleolar ulcers, or infra-malleolar ulcers with previous antibiotic treatment, in patients with diabetes mellitus.
  • Neutropenia
  • Cirrhosis (Child-Pugh class B or C)
  • Intravenous drug use
  • Human or animal bite
  • Skin laceration acquired in fresh or salt open water
  • Fish fin or bone injuries

研究组 & 干预措施

Standard course

Active Comparator

Flucloxacillin (1000mg iv OR, later, 500mg capsules), every 6 hours, for 6 days, followed by: Flucloxacillin 500mg capsules, every 6 hours, for 6 days

干预措施: Flucloxacillin (Drug)

Short course

Experimental

Flucloxacillin (1000mg iv OR, later, 500mg capsules), every 6 hours, for 6 days, followed by: Placebo (for flucloxacillin 500mg) 500mg capsules, every 6 hours, for 6 days

干预措施: Flucloxacillin (Drug)

Short course

Experimental

Flucloxacillin (1000mg iv OR, later, 500mg capsules), every 6 hours, for 6 days, followed by: Placebo (for flucloxacillin 500mg) 500mg capsules, every 6 hours, for 6 days

干预措施: Placebo (for flucloxacillin) (Drug)

结局指标

主要结局

Part 1/2: Resolution...

时间窗: day 14

Resolution of cellulitis at day 14, defined as disappearance of warmth and tenderness at the site of infection, with substantial improvement in erythema and edema

Part 2/2: ...without relapse

时间窗: day 28

No recurrence by day 28, defined as the need for additional antibiotic therapy for cellulitis

次要结局

  • Additional antibiotic usage(Up to 90 days)
  • Resolution without relapse(day 28)
  • Health care resource utilisation(Up to 90 days)
  • Subjective speed of recovery(Up to 90 days)
  • Recurrence at day 90(90 days)
  • Objective speed of recovery(Up to 90 days)
  • Time to relapse(Up to 90 days)
  • Health related Quality of Life(Up to 90 days)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

W.J. Wiersinga, MD, PhD

internist, infectious diseases specialist

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

研究点 (11)

Loading locations...

相似试验

Duration of ANtibiotic Therapy for CEllulitis | 临床试验